- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04920149
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome (MesaCAPP)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a multicenter, multinational, randomized, 2-arm, double-blind, phase II clinical study with 2000mg mesalamine (5-ASA) or placebo in LS patients for a 2-year treatment. 260 tumor free carriers of a known genetic mutation in a major MMR gene (including patients in which the polyps are endoscopically removed) will be randomized 1:1 to receive 2000mg mesalamine or placebo. Patients will be identified through local or national registries and through collaboration with sites. Tumor free patients, assessed by white light high resolution colonoscopy, will be randomized to the study. Blood and stool samples will be collected for analysis of microbiota, ctDNA and potential biomarkers. Biopsies of the normal tissue of ascending colon and rectum will be taken at the first and the last colonoscopy.
The aim of the study is to investigate the effect of regular treatment with mesalamine (5-ASA) on the occurrence of any colorectal neoplasia, tumor multiplicity (the number of detected adenomas/carcinomas) and tumor progression in LS patients.
Tumor multiplicity and tumor progression (severity of the neoplastic lesions) will be investigated.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Ann-Sofie Backman, MD PhD
- Phone Number: 46 707515285
- Email: ann-sofie.backman@sll.se
Study Locations
-
-
-
Hvidovre, Denmark, 2650
- Not yet recruiting
- Hvidovre Hospital
-
Contact:
- Lone Sunde, MD PhD
- Email: lone.sunde@gmail.com
-
Principal Investigator:
- Lone Sunde, MD PhD
-
-
-
-
Emilia-Romagna
-
Bologna, Emilia-Romagna, Italy, CAP 40138
- Not yet recruiting
- Dept. of Scientific Medicine and Surgery, University of Bologna
-
Contact:
- Luigi Ricciardiello, MD PhD
- Email: luigi.ricciardiello@unibo.it
-
Principal Investigator:
- Luigi Ricciardiello, MD PhD
-
-
-
-
-
Szczecin, Poland, 71-252
- Not yet recruiting
- Department of Genetics and Pathomorphology of Pomeranian Medical University
-
Contact:
- Jan Lubinski, MD PhD
- Email: lubinski@pum.edu.pl
-
Principal Investigator:
- Jan Lubinski, MD PhD
-
-
-
-
-
Stockholm, Sweden, 171 76
- Recruiting
- Karolinska University Hospital
-
Contact:
- Ann-Sofie Backman, MD PhD
- Email: ann-sofie.backman@regionstockholm.se
-
Principal Investigator:
- Ann-Sofie Backman, MD PhD
-
Umeå, Sweden, 901 85
- Not yet recruiting
- Norrland University Hospital
-
Contact:
- Gustav Silander, MD PhD
- Email: gustav.silander@vll.se
-
Principal Investigator:
- Gustav Silander, MD PhD
-
Uppsala, Sweden, 751 85
- Not yet recruiting
- Akademiska hospital
-
Contact:
- Joakim Folkesson, MD PhD
- Email: joakim.folkesson@sursci.uu.se
-
Principal Investigator:
- Joakim Folkesson, MD PhD
-
-
Gothenburg
-
Göteborg, Gothenburg, Sweden, 416 85
- Not yet recruiting
- Sahlgrenska University Hsospital
-
Contact:
- David Ljungman, MD PhD
- Email: david.ljungman@vgregion.se
-
Principal Investigator:
- David Ljungman, MD PhD
-
-
Skåne
-
Malmö, Skåne, Sweden, 205 02
- Not yet recruiting
- Skåne University Hospital
-
Contact:
- Irene Stenfors, MD
- Email: irene.stenfors@skane.se
-
Principal Investigator:
- Irene Stenfors, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Proven tumor-free (including patients in which the polyps are removed endoscopically) carriers of a germline pathologic mutation in one of the MMR genes including MLH1, MSH2 (including EpCAM) and MSH6
- Male or female subjects with the age of 30 years or older
- Females who have been post-menopausal more than one (1) year or females of childbearing potential using a highly efficient method of contraception with less than 1% failure rate (i.e. oral hormonal contraceptives, hormone implants, hormone injections, sterilization, hormonal or copper intrauterine device, sterilized/vasectomized partner, or diaphragm in combination with a condom, spermicide or birth control pills) or should agree to abstain from heterosexual activity during treatment period. Females of childbearing potential must have a negative pregnancy test at screening and before randomization.
- Signed written informed consent prior to inclusion in the study
Exclusion Criteria:
- Presence of colorectal endoscopically non-removable benign neoplasia (patient can be included if the adenoma is removed)
- Carriers of germline mutations in PMS2
- Patients with history of stage 3 and 4 CRC are excluded
- Presence of metastatic disease
- Regular use of aspirin/ASA: daily use of ≥100mg in more than 3 continuous months within the last year
- Regular use of NSAIDs or COX-2 inhibitors: daily use in more than 3 continuous months within the last year
- Hypersensitivity to 5-ASA
- Patients after any subtotal or total colectomy
- Colorectal surgery within the previous 6 months
- Unwillingness to participate or who is considered incompetent to give an informed consent
- Pregnant or breastfeeding women
- Participation in another clinical study investigating another IMP within 1 month prior to screening
- Renal insufficiency (GFR <30ml/min/1.73m2)
- Severe liver disease or liver failure (elevation of liver enzymes above 3xULN)
- Current or history of serious psychiatric disorder or alcohol/drug abuse that in the opinion of the investigator may impact the assessment of IMP safety and efficacy or protocol adherence
- Prior history of myocarditis or pericarditis. Other severe acute or chronic medical condition such as severe chronic lung (COPD, including asthma, kidney and heart diseases) or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or ability to comply with study procedures, investigational product administration and, in the judgment of the investigator, would make the subject inappropriate for entry into this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mesalamine
Mesalamine (Mesalazine, Pentasa sachet, 5-ASA) 2 g once daily for 2 years.
|
The IMP will be supplied as sachets with slow-releasing granules.
Other Names:
|
Placebo Comparator: Placebo
Placebo for Mesalamine (Mesalazine, Pentasa sachet, 5-ASA) 2 g once daily for 2 years.
|
The IMP will be supplied as sachets with slow-releasing granules.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the occurrence of any colorectal neoplasia in LS patients
Time Frame: End of treatment at 24 months +/- 1 month
|
Occurrence of any colorectal neoplasia (both benign and malignant tumors) between groups is described by absolute frequencies and percentages.
|
End of treatment at 24 months +/- 1 month
|
Change in the occurrence of any colorectal neoplasia in LS patients
Time Frame: End of study at year 6 +/- 3 months.
|
As above.
|
End of study at year 6 +/- 3 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumour multiplicity
Time Frame: End of treatment at 24 months +/- 1 month
|
The number of colorectal neoplasia (both benign and malignant tumors) per patient will be tested between groups by an analysis of variance, adjusting for country and history of cancer before randomization.
In case of non-normally distributed residuals a suitable transformation to achieve normal distribution is considered.
It will be tested whether 5-ASA (low- and high-dose together) reduces the number of any colorectal neoplasia (both benign and malignant tumors; tumor multiplicity) compared to placebo in LS patients at the end of treatment and end of study.
Advanced adenomas are defined by a diameter above 1 cm villous or tubulo-villous histology or high grade dysplasia.
|
End of treatment at 24 months +/- 1 month
|
Tumour progress
Time Frame: End of treatment at 24 months +/- 1 month
|
The tumor progress in 4 ordered stages will be tested between groups stratified for country and history of cancer before randomization. It will be tested whether 5-ASA reduces tumor progression (compared 4 ordinal stages: no colorectal neoplasia / non-advanced adenoma / advanced adenoma / carcinoma) compared to placebo in LS patients at the end of treatment and end of study. Advanced adenomas are defined by a diameter above 1 cm villous or tubulo-villous histology or high grade dysplasia. |
End of treatment at 24 months +/- 1 month
|
Treatment effects
Time Frame: End of treatment at 24 months +/- 1 month
|
The dependence of treatment effects on history of colorectal cancer, sex and patients age will be assessed by modelling interactions between these factors and treatment in the corresponding regression models. If differences between 5-ASA effects and placebo effects on the occurrence of colorectal neoplasia, tumor multiplicity or tumor progression depend on the history of colorectal cancer, sex and patients age will be investigated. |
End of treatment at 24 months +/- 1 month
|
Significant findings & illnesses - adverse events
Time Frame: End of treatment at 24 months +/- 1 month
|
Safety data are described and compared between groups in an exploratory manner to determine the safety concerning 5-ASA in LS patient. Therefore significant findings/illnesses, reported after the start of the study and which meet the definition of an AE, will be recorded in the CRF. Intention to treat set: This analysis set includes subjects who were randomized (and received at least one dose study drug). This analysis set will be chosen for safety assessment. |
End of treatment at 24 months +/- 1 month
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ann-Sofie Backman, MD PhD, Karolinska University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Metabolic Diseases
- Neoplasms
- Neoplasms by Site
- Disease
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Genetic Diseases, Inborn
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Colorectal Neoplasms
- Neoplastic Syndromes, Hereditary
- DNA Repair-Deficiency Disorders
- Syndrome
- Colorectal Neoplasms, Hereditary Nonpolyposis
- Colonic Neoplasms
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Mesalamine
Other Study ID Numbers
- MesaCAPP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lynch Syndrome
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedHigh-Frequency Microsatellite Instability | Mismatch Repair Gene Mutation | Mutation-Negative Lynch Syndrome | Mutation-Positive Lynch SyndromeUnited States
-
San Raffaele UniversityUnita' di Gastroenterologia - Policlinico Universitario di Bari; Unita' di... and other collaboratorsRecruitingLynch Syndrome | MLH1 Gene Mutation | MSH2 Gene Mutation | MSH6 Gene Mutation | PMS2 Gene Mutation | Lynch Syndrome II | Small Bowel Adenocarcinoma | Lynch Syndrome IItaly
-
Tel-Aviv Sourasky Medical CenterRambam Health Care Campus; Rabin Medical Center; Sheba Medical Center; Soroka University...Not yet recruitingLynch Syndrome I (Site-specific Colonic Cancer)Israel
-
Piazza della Vittoria 14 Studio Medico - Ginecologia...Not yet recruitingLynch Syndrome | ContraceptionItaly
-
National Cancer Institute (NCI)RecruitingLynch SyndromeUnited States, Puerto Rico
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
Imperial College LondonEnrolling by invitation
-
Second Affiliated Hospital, School of Medicine,...Completed
-
Hospital Clinic of BarcelonaFundacion Clinic per a la Recerca BiomédicaCompleted
-
PERROD GuillaumeNot yet recruiting
Clinical Trials on Mesalamine
-
Bausch Health Americas, Inc.CompletedUlcerative ColitisUnited States
-
Warner ChilcottCompletedUlcerative ColitisUnited States, Canada, Puerto Rico
-
Warner ChilcottCompletedUlcerative ColitisUnited States, Canada, Puerto Rico
-
ShireCompletedUlcerative ColitisUnited States, Spain, Denmark, Korea, Republic of, Australia, Taiwan, Singapore, Sweden, Belgium, France, United Kingdom, Romania, New Zealand, India, Canada, South Africa, Brazil, Germany, Mexico, Hungary, Portugal, Chile, Netherlands and more
-
ShireCompletedUlcerative ColitisUnited States, United Kingdom, Israel, Canada, Hungary, Poland, Slovakia
-
Bausch Health Americas, Inc.CompletedIrritable Bowel Syndrome With DiarrheaUnited States
-
Holy Stone Healthcare Co., LtdCompleted
-
Bausch Health Americas, Inc.CompletedUlcerative ColitisUnited States
-
Warner ChilcottTerminatedUlcerative ColitisUnited States
-
Warner ChilcottCompletedUlcerative ColitisUnited States